Fiera Capital Corp Has $44.38 Million Stake in Eli Lilly and Company $LLY

Fiera Capital Corp raised its holdings in Eli Lilly and Company (NYSE:LLY) by 7,327.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 41,296 shares of the company’s stock after purchasing an additional 40,740 shares during the quarter. Fiera Capital Corp’s holdings in Eli Lilly and Company were worth $44,380,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of LLY. 10Elms LLP lifted its position in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. increased its position in Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after acquiring an additional 10 shares in the last quarter. Tanager Wealth Management LLP increased its position in Eli Lilly and Company by 2.6% in the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after acquiring an additional 10 shares in the last quarter. Morey & Quinn Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after acquiring an additional 10 shares during the last quarter. Finally, Wealthspan Partners LLC raised its stake in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after acquiring an additional 10 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.6%

Shares of NYSE:LLY opened at $1,149.38 on Tuesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73. The company has a 50 day moving average of $979.60 and a 200-day moving average of $1,013.80. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market cap of $1.08 trillion, a price-to-earnings ratio of 40.83, a P/E/G ratio of 1.24 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the business posted $3.34 earnings per share. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-stage data for retatrutide showed strong weight-loss results and benefits for obesity-linked conditions, helping convince investors that Lilly can extend its lead in the fast-growing GLP-1 market. Reuters: Lilly shares jump as analysts see retatrutide data extending obesity market edge
• Positive Sentiment: Lilly also reported encouraging Phase 3 results for Foundayo (orforglipron), its oral GLP-1 drug, including better A1C control and weight loss than oral semaglutide in a head-to-head study, with FDA submission planned by the end of the second quarter. PR Newswire: Lilly’s oral GLP-1 Foundayo delivered superior A1C control and weight loss
• Positive Sentiment: Additional ADA conference updates showed Foundayo produced meaningful weight loss in women across menopause stages, broadening the potential patient population and supporting the drug’s commercial opportunity. PR Newswire: Foundayo associated with significant weight loss in women at every stage of menopause
• Positive Sentiment: Peer weakness also appears to be helping Lilly: Zealand Pharma’s disappointing GLP-1 data and a selloff in competing obesity names highlighted Lilly’s relative advantage in the weight-loss race. The Motley Fool: A Weight-Loss Rival Just Crashed 23%
• Neutral Sentiment: Lilly’s 340B deadline passed and hospitals are now evaluating the implications; this looks more like a policy/pricing issue than an immediate earnings catalyst. Becker’s Hospital Review: Eli Lilly’s 340B deadline passes
• Neutral Sentiment: Reports that Medicare’s GLP-1 bridge program may test Lilly’s obesity strategy add some uncertainty, but the impact is still unclear. MSN: Eli Lilly faces new test with Medicare GLP-1 Bridge program
• Neutral Sentiment: Lilly also completed a bioavailability study for early-stage asset LY4064809, which is a pipeline update but not likely a near-term stock driver. TipRanks: Lilly advances early-stage asset with completion of LY4064809 bioavailability study

Wall Street Analyst Weigh In

Several research firms have recently commented on LLY. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Friday. Cantor Fitzgerald boosted their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings cut Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.